Investors

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
May 09, 2017
Codexis Reports Financial Results for the First Quarter of 2017
Product sales increase 49% Highlights include signing second multiyear agreement in the food industry and initiating beta testing of first company-developed enzyme for the molecular diagnostics industry Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces financial results for the three months ended March 31, 2017, and provides a business update. “Codexis ... 
May 02, 2017
Codexis to Hold 2017 First Quarter Conference Call on May 9
REDWOOD CITY, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2017 financial results after market close on Tuesday, May 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. Live Call:   U.S. 855 890 8665     ... 
April 07, 2017
Codexis Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $4.00 per share.  Net proceeds to Codexis from the offering are expected to be approximately $20.2 million after underwriting discounts and commissions and estimated offering expenses.  The offering is expected to close on or about April 12... 
April 06, 2017
Codexis Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., April 06, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and c... 
March 31, 2017
Codexis Signs Second Multi-Year Agreement in Food Industry with Tate & Lyle
Codexis to Research and Develop Novel Enzymes Supporting Tate & Lyle’s Food Ingredient Growth Strategies REDWOOD CITY, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the signing of a multi-year development agreement with Tate & Lyle, a global provider of food ingredients and solutions.  This is the second multi-year agreement signed in recent months between Codexis and Tate & Lyle and highlights Codexis’ con... 
March 09, 2017
Codexis Reports 2016 Fourth Quarter and Full Year Financial Results
Achieves 2016 total revenues and gross margin guidance, introduces 2017 financial guidance Conference call begins at 4:30 p.m. Eastern time today Accompanying slide presentation available on Investor section of company website REDWOOD CITY, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2016, and provides a business update. “Our solid fourth quarter per... 
March 02, 2017
Codexis to Hold 2016 Fourth Quarter and Full Year Conference Call on March 9
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2016 financial results after market close on Thursday, March 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. Live Call: U.S. 855 890 8665   ... 
January 06, 2017
Codexis to Offer High-Performance Enzymes for Diagnostics Markets
REDWOOD CITY, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will offer high-performance enzymes for customers using next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in vitro molecular diagnostic applications.  Codexis’ first proprietary enzyme for this market will target improved library preparation for NGS users, and is expected to be available in beta-test format by the second quart... 

Sign up for E-mail Alerts

You may automatically receive Codexis, Inc. information by e-mail




Enter your e-mail address here:
Print Page Print Page | E-mail Page E-mail Page |

Share Page

X
| Financial Tear Sheet Tear Sheet
built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue